PD24-10 INTERIM ANALYSIS OF NCT02458716: FEASIBILITY OF CYTOREDUCTIVE PROSTATECTOMY IN MEN NEWLY DIAGNOSED WITH METASTATIC PROSTATE CANCER
Yuh B, Kwon Y, Shinder B, Kim S, Lee N, Ruel N, Horie S, Byun S, Lee D, Dipaola R, Kim I. PD24-10 INTERIM ANALYSIS OF NCT02458716: FEASIBILITY OF CYTOREDUCTIVE PROSTATECTOMY IN MEN NEWLY DIAGNOSED WITH METASTATIC PROSTATE CANCER. Journal Of Urology 2017, 197: e455-e456. DOI: 10.1016/j.juro.2017.02.1087.Peer-Reviewed Original ResearchInterim analysis of NCT02458716: Feasibility of cytoreductive prostatectomy in men newly diagnosed with metastatic prostate cancer.
Yuh B, Kwon Y, Shinder B, Kim S, Lee N, Ruel N, Kim I. Interim analysis of NCT02458716: Feasibility of cytoreductive prostatectomy in men newly diagnosed with metastatic prostate cancer. Journal Of Clinical Oncology 2017, 35: e578-e578. DOI: 10.1200/jco.2017.35.6_suppl.e578.Peer-Reviewed Original ResearchMetastatic prostate cancerCytoreductive prostatectomyProstate cancerInterim analysisRate of incontinenceAndrogen deprivation therapyDeep venous thrombusMajor complication rateSecondary outcome measuresFirst interim analysisLocal tumor controlLong-term complicationsDeprivation therapyOncologic benefitPostoperative ileusIncontinence ratesPerioperative complicationsPrimary endpointAnastomotic leakComplication rateMinor complicationsLymph nodesMajor complicationsSubsequent therapyTumor control